Confirmed Rare Side Effects of Artesunate
Artesunate, an antimalarial drug, has several rare side effects reported in clinical use and post-marketing surveillance. These occur in less than 1% of patients and include:
- Severe allergic reactions (anaphylaxis): Sudden onset with symptoms like rash, itching, swelling, severe dizziness, or trouble breathing. This is linked to hypersensitivity and requires immediate medical attention.
- Hemolysis: Breakdown of red blood cells, potentially leading to anemia, dark urine, or jaundice, especially post-treatment in malaria patients.
- Hepatitis or liver injury: Elevated liver enzymes, sometimes with jaundice or abdominal pain; reversible upon discontinuation.
- Cardiac arrhythmias: Irregular heartbeats, including QT prolongation, observed in isolated cases.
- Neuropsychiatric effects: Confusion, seizures, or encephalopathy, more common in severe malaria but rare overall.
These are drawn from FDA labeling for IV artesunate (Guilin No. 1 Factory) and WHO pharmacovigilance data.[1][2]
Why These Are Classified as Rare
Frequency is based on large-scale studies like the SEAQHAEM trial (over 2,000 patients) and global adverse event databases. For example, anaphylaxis occurred in 0.2-0.5% of IV doses, while hemolysis post-recovery affected under 1%. Risk rises with higher doses or prolonged use.[3]
Differences Between IV and Oral Forms
Intravenous artesunate (used for severe malaria) shows higher rates of post-artesunate delayed hemolysis (up to 7% in some cohorts, though still rare overall) compared to oral forms, which have fewer systemic effects but similar allergy risks.[4]
Patient Risk Factors
Higher incidence in those with G6PD deficiency (increases hemolysis risk), prior allergies to artemisinins, or concurrent infections. Monitoring includes baseline blood counts and liver function tests.[1]
Management and Reporting
Stop the drug if severe effects appear; supportive care like epinephrine for anaphylaxis or transfusions for hemolysis. Report to FDA MedWatch or equivalent for tracking.[2]
[1]: FDA Prescribing Information for Artesunate
[2]: WHO Guidelines on Artesunate Safety
[3]: NEJM: Post-Artesunate Delayed Hemolysis
[4]: Lancet Infectious Diseases Review